XENE
Xenon Pharmaceuticals Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Neutral
-19/100
Last price
36.41
▼ 0.16 (0.44%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
36.57
Day high
36.56
Day low
35.78
Volume
1.97M
Market cap
$3.53B
P/E (TTM)
—
52W range
35.75 – 72.66
Trailing performance
Returnvs SPY
1W
-2.10%
-4.0%
1M
-38.86%
-40.3%
3M
-48.69%
-52.1%
6M
-36.72%
-51.7%
YTD
-18.76%
-32.7%
1Y
-7.94%
-23.7%
3Y
+10.13%
-71.8%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on XENE open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+52.58K
Net buying
Buy transactions
11
72.16K shares
Sell transactions
4
19.58K shares
Net transactions
+15
Buys less sells
Sell : buy shares
0.3 : 1
Mixed
Insider-held shares
153.98K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 30, 26 | KELLY THOMAS PATRICK Chief Financial Officer |
BUY | 15.00K | $559.74K | Direct |
| Sep 30, 26 | MORTIMER IAN C Chief Executive Officer |
BUY | 30.00K | $1.12M | Direct |
| Sep 1, 26 | SVORONOS DAWN A Director |
CONVERSION | 5.14K | $41.92K | Direct |
| Aug 28, 26 | KENNEY CHRISTOPHER JOHN Officer |
SELL | 7.07K | $425.83K | Direct |
| Aug 11, 26 | GANNON STEVEN Director |
SELL | 10.00K | $640.55K | Direct |
| Jun 5, 26 | PATOU GARY Director |
SELL | 1.32K | $70.25K | Direct |
| Jun 5, 26 | CANNON GILLIAN Director |
SELL | 1.19K | $63.24K | Direct |
| Jun 1, 26 | PATOU GARY Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | SVORONOS DAWN A Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | GANNON STEVEN Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | MACHADO PATRICK Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | GOVER JUSTIN DAVID Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | GAROFALO ELIZABETH AMY M.D. Director |
— | 2.65K | — | Direct |
| Jun 1, 26 | CANNON GILLIAN Director |
— | 2.65K | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CANNON GILLIAN |
Director | 1.46K | Sale |
DIFABIO ANDREA |
Officer | 7.30K | Sale |
GANNON STEVEN |
Director | 1.87K | Sale |
GAROFALO ELIZABETH AMY M.D. |
Director | 2.65K | Conversion of Exercise of derivative security |
GOVER JUSTIN DAVID |
Director | 2.65K | Conversion of Exercise of derivative security |
KELLY THOMAS PATRICK |
Chief Financial Officer | 15.00K | Purchase |
MACHADO PATRICK |
Director | 2.65K | Conversion of Exercise of derivative security |
MORTIMER IAN C |
Chief Executive Officer | 64.22K | Purchase |
PATOU GARY |
Director | 29.80K | Sale |
SVORONOS DAWN A |
Director | 31.37K | Conversion of Exercise of derivative security |
Fundamentals
Market cap$3.53B
Enterprise value$2.60B
Revenue (TTM)$0
Gross profit$-352.48M
EBITDA$-439.19M
Net income$-409.20M
EPS (TTM)$-4.74
Free cash flow$-203.55M
Total cash$930.69M
Total debt$6.42M
Book value / share$12.84
Shares outstanding96.84M
Float90.90M
Short % of float6.66%
Dividend yield0.00%
Beta (5Y)0.60
Valuation & profitability ratios
Trailing P/E—
Forward P/E-7.72
PEG ratio—
Price / sales—
Price / book2.84
EV / revenue—
EV / EBITDA-5.92
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-43.62%
Return on assets-28.02%
Debt / equity0.52
Current ratio21.02
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $7.50M | $0 | $0 | $9.43M | — |
| Operating revenue | $7.50M | $0 | $0 | $9.43M | — |
| Research & development | $300.94M | $210.39M | $167.51M | $105.77M | +43.0% |
| Selling, general & admin | $79.63M | $68.90M | $46.54M | $32.81M | +15.6% |
| Total operating expense | $380.57M | $279.30M | $214.05M | $138.58M | +36.3% |
| Operating income | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -33.6% |
| Net interest income | $26.83M | $41.94M | $27.62M | $8.71M | -36.0% |
| Pre-tax income | -$344.89M | -$238.42M | -$182.69M | -$125.25M | -44.7% |
| Tax provision | $1.02M | -$4.09M | -$292.00K | $118.00K | +124.8% |
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -47.6% |
| Net income to common | -$345.91M | -$234.33M | -$182.39M | -$124.94M | -47.6% |
| Basic EPS | -4.36 | -3.01 | -2.73 | -2.06 | -44.9% |
| Diluted EPS | -4.36 | -3.01 | -2.73 | -2.06 | -44.9% |
| EBIT | -$373.07M | -$279.30M | -$214.05M | -$129.14M | -33.6% |
| EBITDA | -$370.53M | -$276.74M | -$211.99M | -$127.74M | -33.9% |
| Basic shares | 79.25M | 77.89M | 66.89M | 60.54M | +1.7% |
| Diluted shares | 79.25M | 77.89M | 66.89M | 60.54M | +1.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $199.16M | $142.71M | $148.64M | $57.24M | +39.6% |
| Cash & short-term investments | $548.89M | $626.90M | $638.08M | $592.09M | -12.4% |
| Accounts receivable | $1.37M | $1.47M | $874.00K | $986.00K | -6.7% |
| Total current assets | $560.65M | $635.26M | $644.96M | $600.30M | -11.7% |
| Property, plant & equipment | $15.35M | $18.22M | $18.85M | $16.91M | -15.8% |
| Total assets | $633.16M | $798.14M | $964.80M | $754.15M | -20.7% |
| Total current liabilities | $41.79M | $35.59M | $27.27M | $22.70M | +17.4% |
| Total debt | $7.94M | $9.02M | $10.90M | $10.44M | -11.9% |
| Total liabilities | $51.40M | $43.24M | $36.88M | $32.65M | +18.9% |
| Retained earnings | -$1.25B | -$899.47M | -$665.14M | -$482.75M | -38.5% |
| Shareholder equity | $581.76M | $754.90M | $927.92M | $721.50M | -22.9% |
| Working capital | $518.86M | $599.67M | $617.69M | $577.60M | -13.5% |
| Net tangible assets | $581.76M | $754.90M | $927.92M | $721.50M | -22.9% |
| Shares issued | 80.01M | 76.42M | 75.37M | 62.59M | +4.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$345.91M | -$234.33M | -$182.39M | -$125.37M | -47.6% |
| Depreciation & amortisation | $2.54M | $2.56M | $2.06M | $1.41M | -0.7% |
| Stock-based compensation | $53.71M | $50.72M | $32.37M | $20.38M | +5.9% |
| Change in working capital | $4.36M | $5.71M | $5.90M | -$1.28M | -23.7% |
| Operating cash flow | -$279.12M | -$181.39M | -$151.11M | -$101.03M | -53.9% |
| Capital expenditure | -$799.00K | -$3.08M | -$5.62M | -$2.89M | +74.0% |
| Investing cash flow | $218.00M | $165.00M | -$111.39M | -$293.40M | +32.1% |
| Financing cash flow | $117.11M | $12.13M | $353.52M | $278.47M | +865.5% |
| Free cash flow | -$279.92M | -$184.46M | -$156.73M | -$103.92M | -51.7% |
| End cash position | $199.16M | $142.71M | $148.64M | $57.24M | +39.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — |
| Research & development | $99.22M | $88.51M | $87.70M | $77.05M | $74.98M | +12.1% |
| Selling, general & admin | $23.93M | $23.82M | $22.07M | $19.28M | $19.24M | +0.5% |
| Total operating expense | $123.16M | $112.33M | $109.77M | $96.34M | $94.23M | +9.6% |
| Operating income | -$123.16M | -$112.33M | -$109.77M | -$96.34M | -$94.23M | -9.6% |
| Net interest income | $12.14M | $6.91M | $5.34M | $6.21M | $7.20M | +75.8% |
| Pre-tax income | -$111.32M | -$104.87M | -$104.72M | -$90.22M | -$85.33M | -6.1% |
| Tax provision | -$585.00K | -$2.57M | $538.00K | $677.00K | -$626.00K | +77.2% |
| Net income | -$110.74M | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -8.2% |
| Net income to common | -$110.74M | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -8.2% |
| Basic EPS | -1.11 | -1.17 | -1.31 | -1.15 | -1.07 | +5.1% |
| Diluted EPS | -1.11 | -1.17 | -1.31 | -1.15 | -1.07 | +5.1% |
| EBIT | -$123.16M | -$112.33M | -$109.77M | -$96.34M | -$94.23M | -9.6% |
| EBITDA | -$122.60M | -$111.74M | -$109.16M | -$95.69M | -$93.60M | -9.7% |
| Basic shares | 99.61M | 87.35M | 80.13M | 79.25M | 78.95M | +14.0% |
| Diluted shares | 99.61M | 87.35M | 80.13M | 79.25M | 78.95M | +14.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $119.53M | $545.87M | $199.16M | $104.51M | $135.38M | -78.1% |
| Cash & short-term investments | $930.69M | $1.09B | $548.89M | $462.27M | $487.55M | -15.0% |
| Accounts receivable | $1.63M | $1.17M | $1.37M | $812.00K | $1.10M | +39.8% |
| Total current assets | $945.87M | $1.11B | $560.65M | $480.14M | $500.25M | -14.5% |
| Property, plant & equipment | $13.16M | $14.58M | $15.35M | $15.85M | $16.50M | -9.8% |
| Total assets | $1.30B | $1.39B | $633.16M | $607.84M | $674.28M | -6.6% |
| Total current liabilities | $45.01M | $39.81M | $41.79M | $38.34M | $33.05M | +13.0% |
| Total debt | $6.42M | $7.49M | $7.94M | $8.33M | $8.71M | -14.3% |
| Total liabilities | $53.38M | $48.99M | $51.40M | $48.33M | $40.30M | +9.0% |
| Retained earnings | -$1.46B | -$1.35B | -$1.25B | -$1.14B | -$1.05B | -8.2% |
| Shareholder equity | $1.24B | $1.34B | $581.76M | $559.51M | $633.98M | -7.1% |
| Working capital | $900.86M | $1.07B | $518.86M | $441.80M | $467.20M | -15.6% |
| Net tangible assets | $1.24B | $1.34B | $581.76M | $559.51M | $633.98M | -7.1% |
| Shares issued | 96.75M | 96.62M | 80.01M | 77.12M | 76.73M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$110.74M | -$102.30M | -$105.26M | -$90.90M | -$84.71M | -8.2% |
| Depreciation & amortisation | $558.00K | $587.00K | $611.00K | $641.00K | $632.00K | -4.9% |
| Stock-based compensation | $16.73M | $16.89M | $14.12M | $13.71M | $13.71M | -1.0% |
| Change in working capital | $2.43M | -$3.38M | $8.97M | $4.96M | $2.62M | +171.9% |
| Operating cash flow | -$95.39M | -$88.90M | -$81.48M | -$71.75M | -$64.23M | -7.3% |
| Capital expenditure | -$275.00K | -$133.00K | -$318.00K | -$281.00K | -$157.00K | -106.8% |
| Investing cash flow | -$331.24M | -$407.28M | $62.70M | $38.53M | $82.26M | +18.7% |
| Financing cash flow | $26.00K | $843.01M | $113.54M | $2.36M | $65.00K | -100.0% |
| Free cash flow | -$95.67M | -$89.03M | -$81.80M | -$72.03M | -$64.39M | -7.5% |
| End cash position | $119.53M | $545.87M | $199.16M | $104.51M | $135.38M | -78.1% |
Options analytics
Put / call volume
0.41
Call-heavy session
Put / call open interest
4.50
Positioning, not flow
Max pain
72.50
+99.1% from spot
ATM implied vol
6.3%
Nearest strike to spot
Skew (10% OTM)
+12.5%
Puts bid over calls
Call volume
198
Contracts, this expiry
Put volume
82
Contracts, this expiry
Heaviest call OI
55.00
3 contracts
Heaviest put OI
72.50
12 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.16 | -1.11 | +4.4% |
| Mar 2026 | -1.20 | -1.17 | +2.3% |
| Dec 2025 | -1.21 | -1.31 | -8.7% |
| Sep 2025 | -1.16 | -1.15 | +1.2% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.15 | 13 | $0 | 0.0% |
| Next quarter | -1.17 | 13 | $840.93K | 0.0% |
| Current year | -4.63 | 14 | $1.26M | -83.2% |
| Next year | -4.71 | 14 | $26.97M | +2,045.7% |
Analyst targets & ownership
Mean target$73.37
High target$97.00
Low target$46.00
Implied upside101.51%
Analyst count18
ConsensusSTRONG BUY
Strong buy / Buy3 / 15
Hold1
Sell / Strong sell0 / 0
Held by insiders0.16%
Held by institutions107.34%
Institutions holding438
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
37.37
-2.56% from price
SMA 20
43.70
-16.69% from price
SMA 50
54.72
-33.46% from price
SMA 100
56.68
-35.76% from price
SMA 200
53.00
-31.30% from price
EMA 12
39.42
-7.63% from price
EMA 26
45.18
-19.41% from price
EMA 50
50.70
-28.18% from price
RSI (14)
22.3
Oversold
MACD (12,26,9)
-5.76
Hist 0.04
ATR (14)
2.91
7.99% of price
Realised vol 30D
109.8%
Annualised
Bollinger upper
62.11
20, 2σ
Bollinger lower
25.30
20, 2σ
50 / 200 cross
Golden
54.72 vs 53.00
Trend bias
Below 200
-31.30%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.83
Less volatile than market
Correlation to SPY
0.16
Largely independent
Realised vol 30D
109.8%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-48.7%
Peak to trough
Max drawdown 5Y
-48.7%
Peak to trough
ATR 14
2.91
7.99% of price
Beta (reported)
0.60
5Y monthly, from filing
Short interest
Shares short
6.44M
Prior 5.67M
Change vs prior
+13.7%
Shorts adding
% of float
6.66%
Normal
% of shares out
6.66%
Against total outstanding
Days to cover
10.3
Crowded exit
Float
90.90M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 18, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| Sep 18, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
| Sep 18, 26 | Wells Fargo | MAINTAINED | Overweight | Overweight |
| Sep 18, 26 | Deutsche Bank | DOWNGRADE | Buy | Hold |
| Sep 18, 26 | Needham | MAINTAINED | Buy | Buy |
| Sep 18, 26 | Baird | MAINTAINED | Outperform | Outperform |
| Aug 7, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 27, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 12, 26 | JP Morgan | MAINTAINED | Overweight | Overweight |
| May 8, 26 | RBC Capital | MAINTAINED | Outperform | Outperform |
| May 8, 26 | Needham | MAINTAINED | Buy | Buy |
| Mar 16, 26 | Wedbush | MAINTAINED | Outperform | Outperform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-06
Offering Registrations
S-8 · 2026-06-03
Periodic Financial Reports
10-Q · 2026-05-07
Proxy Statements
DEF 14A · 2026-04-22
Corporate Changes & Voting Matters
8-K · 2026-04-13
Corporate Changes & Voting Matters
8-K · 2026-03-13
Corporate Changes & Voting Matters
8-K · 2026-02-26
Corporate Changes & Voting Matters
8-K · 2025-12-01
Headlines
Insiders Are Buying These 2 ‘Strong Buy’ Stocks With Over 60% Upside
TipRanks · 17h ago
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 6d ago
Xenon’s Insider Buying Tops $1.6M – XENE Stock Heads For Best Day In Over Month
Stocktwits · 7d ago
Xenon's AZK Approval Path Unlikely to Be Hurt by Safety Issues, RBC Says
MT Newswires · 7d ago
Xenon Pharmaceuticals Insider Bought Shares Worth $1,121,400, According to a Recent SEC Filing
MT Newswires · 7d ago
Ian Mortimer Receives the 2026 Bloom Burton Award
TMX Newsfile · 9d ago
Defence Therapeutics Appoints Finance Executive Sherry Aulin to Its Board of Directors
TMX Newsfile · 9d ago
Xenon Files Azetukalner NDA as It Pauses Psychiatry Trials for Tolerability Review
MarketBeat · 11d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.